LENVIMA (Eisai Australia Pty Ltd)
Product name
LENVIMA
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
182 working days (255)
Active ingredients
lenvatinib (as mesilate)
Registration type
EOI
Indication
LENVIMA (hard capsules) is now also indicated for the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC).
Registration process
Orphan drug
Sponsors receive a fee waiver to help bring medicines for a small population to market.